Loading clinical trials...

Nasal High Flow Therapy 30 Day Readmission Study | Clinical Trials | Clareo Health

TERMINATEDNA

Nasal High Flow Therapy 30 Day Readmission Study

Nasal High Flow (NHF) Therapy Use Following Hospitalization for an Exacerbation of COPD: A Feasibility Study

NCT02552732•Fisher and Paykel Healthcare

Summary

The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age or older
•Male and female
•Admitted to the respiratory ward(s) of either recruiting hospitals with AECOPD as the primary diagnostic reason for admission.

Exclusion Criteria

•Given a new home oxygen therapy prescription during the current hospital admission
•The investigator believes the participant or their care giver will be unable to safely use the myAIRVO 2 device following discharge
•They have any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results

Locations (2)

Alana HealthCare

Liverpool, New York, United States

Medical Research Institute of New Zealand

Wellington, New Zealand

Key Dates

Start Date

November 1, 2015

Primary Completion Date

May 3, 2017

Completion Date

May 3, 2017

Last Updated

August 17, 2020

Enrollment

ACTUAL participants

Conditions

Chronic Obstructive Pulmonary DiseaseCOPD

Interventions

NHF with or without Oxygen

DEVICE

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

Effect of Telenursing on Oral Health

NCT07462221

COPD

View study

RECRUITINGPHASE3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Nasal High Flow Therapy 30 Day Readmission Study

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

Effect of Telenursing on Oral Health

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD

Probiotics in Pulmonaty Rehabilitation for COPD

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine